Dr. Bradford Scott Hoppe, MD, MPH

Dr. Hoppe practices at Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic.

Dr. Hoppe's NPI, 1275791055, was assigned on May 28, 2008. Dr. Hoppe graduated from Weill Cornell Medicine in 2002. Dr. Hoppe holds Florida license ME101525.

Dr. Hoppe's primary practice is Mayo Clinic Hospital, at 4500 San Pablo Rd, Jacksonville, FL 32224 in Duval County. The practice phone is (904) 953-2000.

Dr. Hoppe's primary practice is Mayo Clinic Hospital in Jacksonville, Florida, part of Mayo Clinic. The medical group on file is Mayo Clinic Jacksonville.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Hoppe practices. Vendor and product names are available with a free account.

Radiation oncology is Dr. Hoppe's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Hoppe is board certified in radiation oncology by the American Board of Radiology. Dmand AI has Dr. Hoppe's licenses on file in 2 states: Florida and New York.

Dmand AI lists bone cancer radiation, brain cancer radiation, colorectal cancer radiation, lung cancer radiation, lymphoma radiation and prostate cancer radiation among the conditions Dr. Hoppe treats.

CMS data shows 2,033 Medicare services from Dr. Hoppe across 20 procedure codes in 2024, for 303 Medicare patients. Medicare paid $175,727 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 303 Medicare patients who saw Dr. Hoppe in 2024. The largest group is 65 to 74, with 149 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 1.91, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Hoppe's median patient age at 74, with 44% women.

In 2024, Dr. Hoppe wrote 27 Medicare Part D claims for 21 patients. 96% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $123 in total drug cost. In 2022, CMS named 11 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Hoppe for performance year 2024, reported as part of a group. Dr. Hoppe accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Hoppe as offering telehealth.

Dmand AI links 172 papers to Dr. Hoppe, published from 2004 to 2025. 2019 was the busiest year, with 17. The most frequent topics are Proton Therapy, Hodgkin Disease and Radiotherapy Dosage. Dr. Hoppe has published most often in Int J Radiat Oncol Biol Phys. Dr. Hoppe's most frequent co-authors are Nancy P. Mendenhall, MD, Romaine Charles Nichols, MD and William M. Mendenhall, MD.

Dmand AI links Dr. Hoppe to 3 clinical trials. 1 is still active or recruiting. Conditions studied include Carcinoma, Non-Small-Cell Lung, Carcinoma, Bronchogenic and Hodgkin Disease. University of Florida sponsors the most, 2.

CMS Open Payments shows 7 general payments to Dr. Hoppe from 4 drug and device companies from 2016 to 2022. Consulting fees make up the largest share, 99% of the total. Merck Sharp & Dohme Corporation paid the most, $8,750.

Dmand AI lists 3 awards for Dr. Hoppe, most recently Term Professorship in 2019. Dr. Hoppe serves on NCI Lymphoma Steering committee, COG Hodgkin Lymphoma steering committee and ILROG steering Committee.

Dr. Hoppe graduated from Weill Cornell Medicine in 2002.

Dr. Hoppe is in network with 10 carriers, including Excellus BlueCross BlueShield, Elevance and Blue Cross Blue Shield of Michigan. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.